Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 2/20 | 0.49 |
| ▸ | EDNRB | P24530 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30784566 | 1.00 | CA1 (0.56) | CA1CA2CA4CA6MAPT | |
| SCHEMBL4731653 | 0.84 | CYP1A2 (0.55) | CA1CA2CA4CA6CYP1A2 | |
| SCHEMBL9577233 | 0.83 | ALDH1A1 (0.45) | CA1CA2CA4CA6MAPT | |
| SCHEMBL31371128 | 0.82 | ALDH1A1 (0.44) | CA1CA2CA4CA6MAPT | |
| SCHEMBL6743749 | 0.80 | CA1 (0.58) | CA1CA2CA4CA6MAPT | |
| SCHEMBL264098 | 0.79 | CA1 (0.52) | CA1CA2CA4CA6MAPT | |
| SCHEMBL30565211 | 0.79 | CA1 (0.52) | CA1CA2CA4CA6MAPT | |
| SCHEMBL15915609 | 0.79 | EDNRA (0.54) | CA1CA2CA4CA6MAPT | |
| Dimethylamine SCHEMBL8854262 | 0.79 | CA1 (0.47) | CA1CA2CA4CA6MAPT | |
| SCHEMBL1767645 | 0.78 | CA1 (0.56) | CA1CA2CA4CA6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547204-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | claimed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | claimed |
| EP-4514784-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025038395-A1 | BENZOPYRIDINONES AND BENZOPYRIMIDINONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| CN-119301106-A | Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-112778276-B | Compounds as SHP2 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024026424-A1 | QUINAZOLINONE DERIVATIVES AS AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | disclosed |
| CN-102056897-A | Sulfonamide compound and application thereof | ASAHI KASEI PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| EP-2292592-A1 | SULFONAMIDE COMPOUND AND APPLICATION THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | CA1 4791/4885CA2 2748/4885CA4 3568/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | CA1 4669/4885CA2 3132/4885CA4 4219/4885 |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | STS, ARSA, TST | CA1 4599/4885CA2 3102/4885CA4 3878/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | CA1 4791/4885CA2 2748/4885CA4 3568/4885 |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN7 | CA1 1193/4885CA2 674/4885CA4 1109/4885 |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | PTH1R, CASR, SOST | CA1 65/4885CA2 36/4885CA4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.